CT scan analysis shows that fat density increases during treatment, indicating smaller, healthier adipocytes (fat cells) rather than the enlarged, dysfunctional adipocytes associated with metabolic disease
Clinical trial data demonstrate that tirzepatide produces superior A1C reduction and weight loss compared to selective GLP-1 agonists, though the precise mechanisms underlying this enhanced efficacy are not fully elucidated
Michael Chichak, M.D., an internal medicine instructor at Northeast Ohio Medical University and ONE Health Ohio
Conclusion The GLP-1 hormone is recognized as an effective target for the treatment of T2DM due to its multifaceted role in glucose regulation
Please note that not all customers will medically qualify for prescription medications
Daily Amount A daily intake of 2-3 servings is typically suggested, although this may vary based on age and specific health conditions